Analysis of endothelial cells in rheumatoid arthritis

Study ID
STU 012011-034

Cancer Related
No

Healthy Volunteers
Yes

Study Sites

  • UT Southwestern-Other
  • UT Southwestern-Clinical Translational Research Center (CTRC)
  • UT Southwestern Ambulatory Services
  • Parkland Health & Hospital System

Contact
Elizabeth Solow
214-645-2070
elizabeth.solow@utsouthwestern.edu

Principal Investigator
Elizabeth Solow

Summary

aim 1 will consist of a cross sectional analysis of venous endothelial cells in rheumatoid arthritis patients who have controlled or uncontrolled disease and healthy controls. We will collect endothelial cells by placing an iV in antegrade position in the forearm and a thin wire will be inserted to collect the cells from the inner lining of the vein. The cells will processed and stained for markers of endothelial function and oxidative stress including enoS, phospho-enoS, nFkB, and nitrotyrosine using immunofluorescence technique. Flow mediated dilation (FMD) by ultrasound of the brachial artery on the contralateral arm will be used as an additional marker of endothelial function. a blood sample will be taken for analysis of inflammatory markers (eSR, CRP) and cytokine analysis (iL-1, iL-6, TnFa) by cytokine bead array.

aim 2 will follow patients with rheumatoid arthritis longitudinally. Patients identified as having uncontrolled rheumatoid arthritis will undergo collection of endothelial cells by an iV placed in the antegrade position in the forearm followed by a thin wire inserted to collect the cells from the inner lining of the vein. The cells will processed and stained for markers of endothelial function and oxidative stress including enoS, phospho-enoS, nFkB, and nitrotyrosine using immunofluorescence technique. Flow mediated dilation (FMD) by ultrasound of the brachial artery on the contralateral arm will be used as an additional marker of endothelial function. a blood sample will be taken for analysis of inflammatory markers (eSR, CRP) and cytokine analysis (iL-1, iL-6, TnFa) by cytokine bead array. The patient will subsequently initiate the anti-TnF therapy prescribed by their treating rheumatologist. Four weeks following initiation of anti-TnF the procedures described above will be repeated.

Participant Eligibility

AIM 1:
Rheumatoid arthritis:
- Age 18-75 years
- Rheumatoid arthritis defined by 1997 ACR criteria
- Attending clinic at UT Southwestern Aston Clinic for Rheumatology or Parkland Rheumatology Clinic.
Healthy controls:
- Age 18-75 years.

AIM 2:
-Rheumatoid arthritis: defined by 1997 ACR criteria
-Uncontrolled rheumatoid arthritis: if DAS score is >3.2 and CRP (mg/dL) elevated above normal range
-Age 18-75 years
-Attending clinic at UT Southwestern Aston clinic for rheumatology or Parkland Rheumatology Clinic
-Planning to start etanercept or adalimumab by their treating rheumatologist.